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Brief description – “Novelty and Impact” 63 
Head and neck cancer (HNC) is a complex and difficult-to-treat malignancy that leads to 64 
severe disabilities and high mortality. We investigated if, after major improvements in 65 
diagnosis and therapeutic modalities, HNC survival has increased in Europe, and what are 66 
the main determinants of outcome. We found that survival from HNC remains low in 67 
Europe and, alongside with late stage at diagnosis, older age at diagnosis and smoking 68 
are strong predictors of outcome.  69 
 70 
Abstract 71 
Head and neck cancer (HNC) is a preventable malignancy that continues to cause 72 
substantial morbidity and mortality worldwide. Using data from the ARCAGE and Rome 73 
studies, we investigated the main predictors of survival after larynx, hypopharynx and oral 74 
cavity (OC) cancers. We used the Kaplan-Meier method to estimate overall survival, and 75 
Cox proportional models to examine the relationship between survival and 76 
sociodemographic and clinical characteristics. 604 larynx, 146 hypopharynx and 460 OC 77 
cancer cases were included in this study. Over a median follow-up time of 4.6 years, nearly 78 
50% (n=586) of patients died. Five-year survival was 65% for larynx, 55% for OC, and 35% 79 
for hypopharynx cancers. In a multivariable analysis, we observed an increased mortality 80 
risk among older (≥71 years) vs. younger (≤50 years) patients with larynx/hypopharynx 81 
combined (LH) and OC cancers [HR=1.60, 95% CI 1.09–2.37 (LH) and HR=2.10, 95% CI 82 
1.34–3.29 (OC)], current vs. never smokers [HR=2.70, 95% CI 1.42–5.14 (LH) and 83 
HR=2.11, 95% CI 1.29–3.46 (OC)], and advanced vs. early stage disease at diagnosis [IV 84 
vs. I, HR=2.61, 95% CI 1.78–3.81(LH) and HR=3.22, 95% CI 2.08–4.96 (OC)]. Survival 85 
was not associated with sex, alcohol consumption, education, oral health, p16 expression, 86 
presence of HPV infection, or body mass index 2 years before cancer diagnosis. Despite 87 
advances in diagnosis and therapeutic modalities, survival after HNC remains low in 88 
Europe. In addition to the recognized prognostic effect of stage at diagnosis, smoking 89 
history and older age at diagnosis are important prognostic indicators for HNC.  90 
  91 
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Introduction 92 
Head and neck cancer (HNC) is mostly comprised of oral cavity, oropharynx, hypopharynx, 93 
and larynx tumors. When taken together, HNC represents the 5th most common 94 
malignancy in males in the high-income countries, with a lower incidence among females 95 
(male to female ratio varies from 2:1 to 4:1).1 Over 90% of cases are squamous cell 96 
carcinomas.2 HNC can be cured if the tumor is diagnosed at early stage and limited to the 97 
head and neck region. However, prognosis is very poor when HNC is diagnosed at later 98 
stages with metastatic or recurrent disease. A decision between aggressive multimodality 99 
and function-preserving treatment should be based on patient’s health and comorbidities, 100 
and on the extent to which therapy may affect the patient’s quality of life.3  101 
 Tobacco exposure (including active and smokeless tobacco use) and alcohol 102 
consumption are well-established risk factors for HNC.4 Human Papillomavirus (HPV) 103 
infection is an additional independent risk factor for oropharynx cancer. Studies have 104 
shown that HPV-related HNC is genetically and biologically different from smoking-105 
associated HNC, with HPV-related HNC demonstrating improved clinical outcomes.3 HPV 106 
positive oropharynx cancer patients commonly have greater survival than HPV negative 107 
cases.5-7 However, the same HPV causal and prognostic associations have not been 108 
observed for larynx, hypopharynx, or oral cavity cancer where HPV infections are rare.8  109 
Stage at diagnosis has been considered one of the strongest predictors of survival 110 
among patients with HNC,9 whereas the role of smoking and alcohol on survival remains 111 
controversial. Robust epidemiological data may help to identify modifiable prognostic 112 
factors and guide cancer prevention programs aimed to reduce the burden of HNC 113 
worldwide.10 In this study we focused on the determinants of survival from larynx, 114 
hypopharynx, and oral cavity cancers in Europe. A separate study has examined survival 115 
from oropharynx cancer including the role of HPV.11  116 
117 
15-January-2018
Page 5 of 27 
Patients and methods 118 
Patients 119 
Data was obtained from 14 centers located in 9 European countries. Thirteen centers were 120 
participants of the ARCAGE* case-control study12 as follows: Czech Republic (Prague), 121 
Germany (Bremen), Greece (Athens), Italy (Aviano, Padova, and Turin), Ireland (Dublin), 122 
Norway (Oslo), United Kingdom (Glasgow, Manchester, and Newcastle), Spain 123 
(Barcelona), and Croatia (Zagreb). The remaining data were obtained from a case-control 124 
study in Rome.13 The recruitment of cases was performed from 2002 to 2005 for the 125 
ARCAGE study (n=1,066) and from 2003 to 2011 for the Rome study (n=144). Details of 126 
the ARCAGE and Rome projects can be found elsewhere.12,13 127 
Cases eligible for inclusion in our study were all patients with a primary squamous 128 
cell carcinoma of the larynx, hypopharynx or oral cavity confirmed by histology or cytology. 129 
We included the following topography codes from the International Classification of 130 
Diseases for Oncology, 3rd edition (ICD-O-3)14: C320-C32.9 for larynx, C12.9 and C13.0-131 
C13.9 for hypopharynx, and C00.3-C00.9, C02.0-C02.3, C03.0-C03.9, C04.0-C04.9, 132 
C05.0, and C06.0-C06.9 for oral cavity cancers. Following a standard protocol, participants 133 
underwent an identical questionnaire-based interview within 6 months of diagnosis in order 134 
to obtain sociodemographic information, complete lifetime smoking and alcohol histories, 135 
dietary habits, dental health and care, and education level attained. Biological samples 136 
(blood and/or tumor blocks) were also collected. Data on stage at diagnosis, overall 137 
treatment, and clinical outcome were subsequently obtained from population-based 138 
registries, medical records, linkage with regional or national death index, as well as 139 
doctor’s contact. Participants were followed from the date of diagnosis to the date of death, 140 
loss to follow-up or end of study (31st December 2011), whichever occurred first. Patient’s 141 
follow-up was performed once from 2012 to 2015 to obtain last known vital status (alive, 142 
death, or lost to follow-up) and date of last contact. 143 
144 
Sociodemographic, clinical and lifestyle variables 145 
The sociodemographic, clinical and lifestyle variables were classified as follows. Age at 146 
diagnosis was categorized in 4 groups (≤50, 51–60, 61–70, and ≥71 years). Tumor stage 147 
at diagnosis was classified in stage I to IV based on the TNM system of the American Joint 148 
Commission on Cancer (AJCC) Staging Manual, 6th edition.15 Smoking was examined in 149 
*Alcohol-Related Cancers and Genetic Susceptibility in Europe
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3 different ways: overall history (never, former or current smokers), duration (never, 1–9, 150 
10–19, 2029, 30–39 and ≥40 years), or intensity (number of pack of cigarettes per year: 151 
never, <20, 20–39, 40–59, ≥60). Smokers were individuals who used any tobacco product 152 
(estimated based on cigarette equivalents) at least once a week for one year. Alcohol 153 
consumption was also examined in 3 ways: overall history (never, former or current 154 
drinkers), duration (never, 1–9, 10–19, 20–29, 30–39 and ≥40 years), and intensity 155 
(number of drinks per day: <5 or ≥5). Information on overall smoking and alcohol histories 156 
were obtained from all centers, whereas Rome did not have information on duration and 157 
intensity of these variables. Therefore, overall histories were included in the main models 158 
and separate models, excluding Rome cases, waere performed to examine the effect of 159 
smoking and alcohol duration and intensity on survival, and were included in the 160 
supplementary materials (Table S1). 161 
 Education was categorized as level of education attained by the time of diagnosis: 162 
primary school, secondary school or university degree. Body mass index (BMI, kg/m2): 163 
was examined using self-reported height and weight 2 years before cancer diagnosis, 164 
which decreases the probability that low BMI is secondary to cancer development.16 BMI 165 
was classified according to the World Health Organization into 4 categories: underweight 166 
(<18.5), normal weight (18.5–24.9), overweight (25.0–29.9) and obese (≥30.0). Dental 167 
care and oral hygiene scores were created and classified as good, moderate, and poor as 168 
described elsewhere.17  169 
 Binary variables were sex (male/female) and the HPV tumor markers HPV16 DNA 170 
and p16 protein expression (positive/negative). HPV16 DNA genotyping was done using 171 
the type-specific E7 polymerase chain reaction bead-based multiplex assay (TS-E7-MPG, 172 
IARC, Lyon, France) as described elsewhere.17 The qualitative assessment of antigen 173 
p16INK4A was performed by immunohistochemistry, using the CINtec Histology kit 174 
according to the manufacturer’s instructions (www.mtmlabs.com). P16 expression was 175 
scored based on the intensity and the proportion of nuclear and cytoplasmic stained cells, 176 
and was considered positive when the combined score was equal to 4 or higher. Studies 177 
have shown that combined p16 expression and HPV16 DNA testing are needed to predict 178 
outcome for HNC.18 We examined p16 expression alone and combined with HPV16 DNA 179 
as follow: p16 (–) DNA (–), p16 (+) DNA (–), p16 (+) DNA (+), and p16 (–) DNA (+). In 180 
addition to the variables above, we provided a descriptive analysis on relapse occurrence 181 
and overall treatment.  182 
 183 
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Statistical analyses 184 
We used the Kaplan-Meier method to estimate 2-, 5- and 8-year overall (all-cause) 185 
survival, and used the log-rank test to examine differences in survival across strata of each 186 
variable. Overall survival is presented by anatomic site and, sample size allowing, by tumor 187 
subsite (glottis vs. supraglottis, tongue vs. other regions of the mouth, as well as pyriform 188 
sinus and other hypopharynx regions).  189 
 Multivariable Cox regression models were used to obtain the hazard ratios (HRs) of 190 
death and corresponding 95% confidence intervals (CI). We used the likelihood ratio test 191 
as an overall significance test for the association of each independent variable with the 192 
hazard ratio of death. We tested the proportional hazard (PH) assumption by examining 193 
log-log survival plots, and confirmed the results by using Schoenfeld’s global test. The PH 194 
assumption was met for all variables in the multivariable models. We included in the 195 
multivariable models the variables with a priori hypothesized or previously observed 196 
associations with survival (sex, age and stage at diagnosis, smoking and alcohol histories, 197 
BMI 2 years before diagnosis, education level, and dental care). A separate model was 198 
performed to examine the association between HPV tumor markers and survival. 199 
 Given the modest number of hypopharynx cases, they were pooled with larynx 200 
cases for the multivariable analysis. When we performed separate Cox models, we 201 
observed the same pattern of associations for both larynx and hypopharynx cases, but 202 
with larger confidence intervals and p-values for hypopharynx cases due to the smaller 203 
sample size. Cases from Rome did not provide data on education, BMI pre-diagnosis and 204 
oral health. Missing data were handled by including them as “unknown” categories in the 205 
multivariable models (omitted in the tables). A complete analysis where missing data were 206 
excluded was also conducted, and similar results were obtained. We tested for interactions 207 
between tumor sites and each variable and found no significant interaction. Statistical 208 
analyses were performed using Stata 14 software (StataCorp, College Station, TX, USA), 209 
and a 2-sided p-value of less than 0.05 was considered statistically significant. 210 
 211 
Ethics approval 212 
The ARCAGE study was approved by the Ethical Review Board of the International Agency 213 
for Research on Cancer (IARC), as well as the respective local boards in the individual 214 
participating centers. The Rome study was approved by the ethical committee of 215 
Fondazione Policlinico Universitario “A. Gemelli”. All participants provided written informed 216 
consent for their participation in the study.  217 
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Results  218 
A total of 604 (50%) larynx, 146 (12%) hypopharynx and 460 (38%) oral cavity cancer 219 
cases were included in this study. The sociodemographic and clinical characteristics of 220 
patients are summarized by anatomic site in Table 1. Overall, most of patients were males 221 
(82%), ever smokers (91%), and ever drinkers (93%), had a median age at diagnosis of 222 
60 years, and were diagnosed with advanced stage disease (55% stages III or IV vs. 45% 223 
stages I or II). 224 
 225 
Overall survival  226 
The median follow-up time was 4.6 years. Of 1,210 patients, nearly half (n=586) died over 227 
the course of follow-up. Five-year survival was 65% for larynx (95% CI 61.1–69.2), 55% 228 
for oral cavity (95% CI 50.1–59.7) and 35% for hypopharynx (95% CI 26.8–42.5) cancers 229 
(Tables 2A & 2B, Figure1A). When an adequate sample size was available, survival was 230 
also examined by anatomic subsite. Based on the log-rank test, we observed that 5-year 231 
survival was higher among patients with glottic vs. supraglottic cancer (77% vs. 58%), and 232 
for those with tumor of the tongue vs. other regions of the mouth (63% vs. 50%). There 233 
was no evidence of difference in survival between patients with cancer of the pyriform 234 
sinus and other hypopharynx regions (Figures 1B-D). 235 
 For all anatomic sites, we found strong evidence of an association between worse 236 
survival and smoking history (former or current smoker) (Tables 2A & 2B,) or advanced 237 
stage disease at diagnosis (Tables 2A & B, Supplementary Figure S1). Among oral cavity 238 
cancer patients, we also found associations of lower survival with older age at diagnosis, 239 
male sex, lower level of education, and low BMI 2 years before cancer diagnosis). There 240 
was no evidence of survival differences by p16 protein expression alone or combined with 241 
HPV testing for any cancer site (Table 2A & 2B). Survival did not vary by cancer center or 242 
country (data not shown). 243 
 244 
Hazard ratio of death 245 
In a multivariable Cox regression analysis, in which all variables were mutually adjusted 246 
for, we found, among larynx/hypopharynx cases, an increased risk of death for 247 
hypopharynx vs. larynx cancer (HR=2.30, 95% CI 1.79–2.95), older compared to younger 248 
patients (≥71 vs. ≤ 50 years, HR=1.60, 95% CI 1.09–2.37), current vs. never smokers 249 
(HR=2.70, 95% CI 1.42–5.14) and advanced vs. early stage disease at diagnosis (IV vs. 250 
I, HR=2.61, 95% CI 1.78–3.81). Likewise, among oral cavity cancer patients, we observed 251 
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an increased risk of death for older compared to younger patients (≥71 vs. ≤ 50 years, 252 
HR=2.10, 95% CI, HR=1.34–3.29; and 61–70 vs. ≤ 50 years, HR=1.67, 95% CI 1.13–253 
2.47), current vs. never smoker (HR=2.11, 95% CI 1.29–3.46), and for those with 254 
advanced vs. early stage at diagnosis (IV vs. I, HR=3.22, 95% CI 2.08–4.96) (Table 3). 255 
We did not find significant associations between the risk of death and sex, dental care or 256 
BMI 2 years pre-diagnosis.  257 
 In separate analyses, when we used the number of packs of cigarettes smoked per 258 
year or duration of smoking instead of overall smoking history (Rome cases excluded), 259 
similarly strong associations were found. For instance, larynx/hypopharynx patients who 260 
smoked ≥20 cigarette pack years had approximately 3 times higher risk of death than never 261 
smokers. Likewise, for oral cavity cancer, patients who smoked ≥20 cigarette pack years 262 
had a risk of death about 2.5 times higher than never smokers. (Supplementary Table S1) 263 
When we examined alcohol duration and intensity, we also did not find evidence of an 264 
association between the risk of death and alcohol consumption (Supplementary Table S1). 265 
There was no evidence of an association between the risk of death and p16 expression, 266 
whether examined alone or combined with HPV testing (Figure 2, Supplementary Table 267 
S2).  268 
 269 
Descriptive analysis 270 
Data on relapse was available for approximately 80% of cases. Out of 973 patients, 341 271 
(35%) relapsed. Higher incidence of relapse was observed among patients with 272 
hypopharynx (46%), followed by oral cavity (38%) and larynx (30%) cancers (p=0.002). 273 
After excluding cases to whom relapse occurred less than 90 days from diagnosis (n=49), 274 
we observed that the majority of patients (n=194, 72%) relapsed within 2 years of HNC 275 
diagnosis, whereas 19% (n=52) and 9% (n=25) relapsed within >2 to 5 years and >5 to 10 276 
years respectively (Supplementary Figure S2). Time to relapse did not differ significantly 277 
by anatomic site. 278 
 Overall information on type of treatment was available for approximately 97% of 279 
cases. Surgery was performed in most of patients (66%), alone (34%) or combined with 280 
radiotherapy (28%), chemotherapy (1%), or both (11%). About 12% of patients received 281 
radiotherapy alone, 10% received chemotherapy and radiotherapy, and 1% received 282 
chemotherapy alone. For about 2% of patients no type of treatment was reported. 283 
 284 
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Discussion 285 
Our results reveal that survival from head and neck cancer remains low in Europe. Except 286 
for patients with tumors of the glottis, 8-year survival was lower than 50% for all tumor sites 287 
and subsites. In the multivariable models, the main predictors of survival were age at 288 
diagnosis, stage at diagnosis, smoking history, and anatomic site.  289 
 Age at diagnosis is often considered an independent predictor of outcome for many 290 
types of cancer.19,20 The influence of age on HNC survival remains controversial. In a 291 
recent review, which included surgical, radiation-alone, and chemoradiation studies from 292 
1980 to 2012, the authors concluded that even though elderly patients may experience 293 
higher treatment-related toxicities than their younger counterparts, there was not sufficient 294 
evidence that survival is worse among older than younger patients (the majority of the 295 
studies investigated overall rather than disease-free or cancer-specific survival).21 Another 296 
study which use data from the Surveillance Epidemiology and End Results (SEER) 297 
program in the United States (US) and estimated overall survival of patients diagnosed 298 
with larynx, tongue or tonsil cancer between 1988 and 1998, supported these findings.22  299 
In contrast, our findings of increased risk of death among older patients (≥71 years 300 
for larynx/hypopharynx and ≥61 years for oral cavity cancers) support the results of several 301 
population-based studies in Europe and in the US. For instance, a European study used 302 
data from 15 French cancer registries on patients diagnosed with HNC between 1989 and 303 
1997. The authors found that relative survival (which accounts for competing causes of 304 
death) was consistently lower for elderly compared to younger patients. The excess 305 
mortality among patients aged>75 years was apparent during the first 3 months and after 306 
3 years of diagnosis, with no significant influence of age between 1 and 3 years after 307 
diagnosis.23 Likewise, in a later European study on HNC, relative survival was lower among 308 
elderly (≥ 75 years) vs. younger patients diagnosed from 1999 to 2007.9 In the US, a study 309 
from a large university-based cancer registry used data from 1990 to 2005 and found that, 310 
after adjusting for potential confounders, patients with HNC aged ≥70 years at diagnosis 311 
had a risk of death about twice as high as that of patients younger than 70 years.24 Notably, 312 
the authors showed that when older patients with advanced disease (stage at diagnosis 313 
III–IV) were treated with multimodality therapy, 5-year overall survival was close to that of 314 
younger patients who received similar therapeutic management. However, older patients 315 
who received single-modality treatment had dramatically lower 5-year survival than their 316 
younger counterparts. Older age is commonly associated with moderate to severe 317 
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comorbidities, which may diminish the patient’s ability to tolerate surgery and intensive 318 
cancer adjuvant treatment, such as radiotherapy and/or chemotherapy.10 Comorbidities 319 
such as cardiovascular and pulmonary diseases in HNC patients are mostly secondary to 320 
smoking and excessive alcohol use. In addition, advanced age is associated with a decline 321 
in immune function,25-27 which may not only facilitate cancer progression, but also weaken 322 
the host immune response against cancer.10 Nonetheless, studies suggest that, since 323 
cancer is the main cause of death among elderly patients with advanced HNC, the 324 
competing causes of death likely contribute to a small fraction of the lower survival 325 
observed among these patients.24 The main challenge in the treatment of elderly patients 326 
with HNC is to decide for which patients the benefit of intensive multimodality therapy 327 
compensates the risk of treatment toxicity.  328 
 Stage at diagnosis is widely considered a main determinant of cancer survival and 329 
this is also true for HNC.9 Our results showed that even with the advance on diagnosis 330 
procedures observed in the last decades, the majority of patients (55%) with HNC are still 331 
diagnosed with advanced disease (stage III–IV) in Europe. This proportion is close to the 332 
EUROCARE-5 study,9 which used data from 29 European countries on patients diagnosed 333 
from 1999 through 2007. The authors emphasized that over 54% of patients were 334 
diagnosed with regional or metastatic disease. We found that the risk of death was 335 
approximately 2 or 3 times greater among patients with stage III or IV, respectively, than 336 
those with stage I at diagnosis. While HNC can be often cured when diagnosed at early 337 
stage, late stage disease may be untreatable or involve aggressive multimodality treatment 338 
that often leads to severe physical and psychological disabilities. It has been reported that 339 
HNC have the highest risk of disability and work quitting, together with central nervous 340 
system and hematologic malignancies28 341 
 We observed a strong association between smoking and survival. This association 342 
was significant for all investigated variables (overall smoking history, duration, and 343 
intensity) and highlights the importance of intensifying tobacco prevention and control in 344 
Europe. According to the World Health Organization, smoking kills closely 6 million people 345 
per year, more than HIV/AIDS, malaria and tuberculosis combined. It has been estimated 346 
that this number can increase to over 8 million people by 2030 if more immediate and 347 
severe actions are not taken.29 While some previous studies had shown negative30,31 or 348 
limited32,33 association between smoking and HNC survival, our findings support a large 349 
population-based study conducted in Ireland which revealed that smoking at diagnosis was 350 
associated with worse survival.34 The authors highlighted that this association was 351 
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stronger among patients who had surgical treatment for their HNC, and neither 352 
chemotherapy nor radiotherapy influenced the effect of smoking on survival. One relevant 353 
question in the clinical setting is whether smoking cessation after cancer diagnosis can 354 
improve prognosis of HNC, for instance decreasing treatment complications and the risk 355 
of relapse or second primary malignancy.35 Post-treatment smoking history was not 356 
available in our study.  357 
 While our results support the influence of smoking on survival from HNC, we did not 358 
find the same association regarding alcohol consumption and survival when we examined 359 
overall alcohol history, duration or intensity. Our findings differ from a US study36 which 360 
found that alcohol consumption pre- and post-diagnosis adversely affected HNC survival, 361 
and highlighted the need for aggressive interventions to help patients to abstain from or 362 
decrease alcohol intake. In another US study,37 which enrolled over 1,000 patients with 363 
HNC, about 17% of patients had secondary tumors. Strikingly, alcohol consumption 364 
combined with smoking after diagnosis was found to significantly increase the risk of 365 
secondary tumors among these patients. More studies in Europe are needed to investigate 366 
the association between alcohol pre- and post-diagnosis and HNC outcomes. 367 
 In our study, HNC prognosis varied significantly by anatomic site, with better 368 
survival for larynx, intermediate for oral cavity, and worse for hypopharynx cancer patients. 369 
These results are consistent with previous survival studies in Europe. For example, the 370 
EUROCARE II study,38 which used data from 17 countries on patients diagnosed from 371 
1985 to 1989, revealed that overall, 5-year relative survival was approximately 63% for 372 
larynx, 41% for oral cavity, and 22% for hypopharynx cancer, with wide geographic 373 
variations (higher survival in Western than Eastern European countries). The authors 374 
suggested that possible reasons for the observed survival disparities are late diagnosis, 375 
late referral to treatment, and lack of access to effective treatment. The subsequent 376 
EUROCARE-5 study9 showed that 5-year relative survival after larynx cancer has not 377 
improved over time (from 1999–2001 to 2005–2007), whereas survival improved by 3–5% 378 
(absolute difference) for oral cavity, oropharynx, and hypopharynx. However, 5-year 379 
relative survival was still low: 25% for hypopharynx and 45% for oral cavity cancer patients. 380 
Although our results are not directly comparable, the same survival pattern was observed 381 
in our cohort of patients, suggesting no or little improvement in the last few decades, 382 
despite progresses in diagnosis procedures and therapeutic management. This finding is 383 
concerning and emphasizes the need for increased healthcare policy aimed at decreasing 384 
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modifiable risk factors (such as smoking and alcohol consumption) for HNC occurrence in 385 
Europe. 386 
 Curative treatment for HNC is complex and often negatively impacts patient's quality 387 
of life (e.g. causing difficulty to speak, breath, swallow, as well as facial deformity). 388 
Advancements in treatment such as new surgical techniques, the use of concurrent or 389 
alternating chemoradiation, hyperfractionated or accelerated radiotherapy, and more 390 
recently immunotherapy, may improve HNC survival and reduce the burden of 391 
complications secondary to treatment.39 However, improvement in HNC outcomes have 392 
been disappointing. Despite treatment advances, larynx cancer is one of the few types of 393 
cancer in which survival has recently decreased in the US (from 66% during 1975–1977 394 
and 1987–1989 to 63% during 2005–2011).40 It has been postulated that the declining 395 
survival trends are due to changes in treatment toward a nonsurgical (organ preservation) 396 
approach.41,42  397 
 For hypopharynx cancer, a recent population-based study43 using SEER data 398 
showed evidence of increasing survival trends since 1990: 5-year overall survival improved 399 
from 38% during 1973–1989 to 41% during 1990–2003. Through the study period, there 400 
was a trend toward reduced surgical treatment and increased use of radiation-only therapy. 401 
In contrast to what has been observed for larynx cancer in the US, this study suggests that 402 
organ preservation may have a survival benefit for hypopharynx cancer patients. For oral 403 
cavity cancer, surgery remains the first-line treatment, while44 radiotherapy and lymph 404 
node resection are usually performed for advanced stage disease or for those patients 405 
considered ineligible for surgical interventions. 406 
 It has been recognized that approximately 50% of patients with HNC have 407 
substantial weight loss at diagnosis and just before start of therapy in consequence of 408 
cancer symptoms (e.g. dysphagia, odynophagia, and anorexia),45 and this has been 409 
shown to negatively impact survival.46 Therefore, we aimed to investigate whether BMI 2 410 
years before diagnosis also influence survival after HNC. After multiple adjustments, we 411 
did not observe a significant association between the risk of death and underweight, which 412 
may be explained by the small number of patients in this category (fewer than 3.5%). 413 
Likewise, overweight or obesity pre-diagnosis was not found to impact survival among our 414 
patients. 415 
 Finally, when tumor samples were available, we evaluated whether p16 expression 416 
alone or associated with HPV16 testing predicts prognosis for non-oropharynx cancers. 417 
P16 is a tumor suppressor gene considered a good proxy for HPV infection in tumors.3 418 
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Our results support the lack of an association between survival and p16 overexpression 419 
examined alone, as reported by other authors.47,48 We also did not find any association 420 
with survival when p16 was considered with HPV DNA testing.  It is possible that, in our 421 
study, the small number of HNC cases that were both HPV DNA and p16 positive have 422 
contributed for the negative association we observed. Further studies to investigate the 423 
prognostic role of these markers on non-oropharynx cancer outcomes are warranted. 424 
 Our study has several limitations. Since the ARCAGE study was initially designed 425 
to look at risk factors of head and neck cancer, collection of clinical data such as detailed 426 
treatment approach and relapse (including dates of treatment and relapse) were restricted. 427 
Therefore it was not possible to investigate the impact of treatment modality on survival or 428 
relapse. We used self-reported weight and height 2 years before diagnosis, which may be 429 
subject to inaccuracy and bias. However, previous studies have shown high correlation 430 
(r>0.9) between self-reported and measured height, weight and BMI. 49,50 Overall, data 431 
were missing on stage at diagnosis in about 21% of cases. However, the strong 432 
association we found between stage at diagnosis and survival supports previous studies 433 
and emphasizes the impact of late diagnosis on HNC prognosis. Although Rome did not 434 
have information on certain variables, the data provided by this center were valuable and 435 
the associations we found remained even when these cases were excluded from the 436 
analyses. We also lacked information on comorbidities, performance status, and treatment 437 
complications. Although these data would likely have contributed additional findings, 438 
predictors of HNC outcome such as smoking, stage and age at diagnosis are of paramount 439 
importance and were clearly demonstrated in our study. In addition, the strengths of the 440 
ARCAGE study includes a standard protocol, data from several European centers with 441 
detailed information on smoking and alcohol histories, tumor histological or cytological 442 
confirmation for all patients, as well as blood and tumor samples for several cases.  443 
 In summary, HNC is a complex malignancy that involves vital anatomic structures, 444 
which make it difficult to treat. Surprisingly, despite the advances in diagnosis and 445 
therapeutic modalities, survival after HNC remains low in Europe. Most patients continue 446 
to be diagnosed with disease at advanced stage, which often requires aggressive 447 
treatment and may lead to substantial disabilities and psychological disorders, reducing 448 
quality of life among survivors. The association between older age and inferior survival 449 
suggests that treatment should be personalized based on patients’ comorbidities and 450 
tolerability. Importantly, public health efforts in Europe should focus on primary prevention 451 
to deter the initiation of tobacco use, promote smoking cessation, and prevent excessive 452 
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alcohol consumption. In addition, secondary prevention to detect HNC at an earlier stage 453 
is crucial. 454 
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 602 
Table 1: Sociodemographic and clinical characteristics of patients with larynx, hypopharynx, and oral cavity cancers  603 
 604 
Description Larynx, N (%) Hypopharynx, N (%) Oral cavity N (%) 
Total= 1,210  604 (49.9) 146 (12.1) 460 (38.0) 
Age at diagnosis, years    
  Median (IQR) 62 (55-69) 58 (52-64) 59 (52-68) 
  ≤50 75 (12.4) 31 (21.2) 97 (21.1) 
  51–60 195 (32.2) 54 (37.0) 165 (35.9) 
  61–70 219 (36.3) 44 (30.1) 119 (25.9) 
   ≥71 111 (18.4) 17 (11.6) 79 (17.2)  
  Unknown 4 (0.7) 0 0 
Sex    
  Male 526 (87.1) 131 (89.7) 329 (71.5) 
  Female 75 (12.4) 15 (10.3) 131 (28.5) 
  Unknown 3 (0.5) 0 0 
Smoking history    
  Never 35 (5.8) 10 (6.9) 69 (15.0) 
  Former 231 (38.2) 36 (24.6) 107 (23.3) 
  Current 335 (55.5) 100 (68.5) 284 (61.7) 
  Unknown 3 (0.5) 0 0 
Alcohol use history    
  Never 45 (7.4) 0 (0) 39 (8.5) 
  Former 67 (11.1) 24 (16.4) 60 (13.0) 
  Current 482 (79.8) 122 (83.6) 362 (78.5) 
  Unknown 10 (1.7) 0 0 
Stage at diagnosis    
  I 131 (21.7) 8 (5.5) 86 (18.7) 
  II 95 (15.7) 12 (8.2) 93 (20.2) 
  III 111 (18.4) 29 (19.9) 47 (10.2) 
  IV 140 (23.2) 66 (45.2) 134 (19.1) 
  Unknown 127 (21.0) 31 (21.2) 100 (21.7) 
Level of education*     
  Finished primary school 207 (34.3) 47 (32.2) 140 (30.4) 
  Finished secondary school 263 (43.5) 89 (60.0) 270 (58.7) 
  University degree 25 (4.1) 4 (2.7) 20 (4.4) 
  Unknown 109 (18.1) 6 (4.1) 30 (6.5) 
BMI 2 years pre-diagnosis (kg/m2)*    
  Underweight (<18.5) 6 (1.0) 4 (2.7) 14 (3.1) 
  Normal weight (18.5–24.9) 223 (36.9) 66 (45.2) 193 (42.0) 
  Overweight (25.0–29.9) 181 (30.0) 49 (33.6) 151 (32.8) 
  Obesity (≥30) 79 (13.1) 18 (12.3) 54 (11.7) 
  Unknown 115 (19.0) 9 (6.2) 48 (10.4) 
Dental care*    
  Good  85 (14.1) 27 (18.5) 79 (17.2) 
  Moderate 397 (65.7) 106 (72.6) 338 (73.5) 
  Poor 9 (1.5) 5 (3.4) 9 (2.0) 
  Unknown 109 (18.7) 8 (5.5) 34 (7.4) 
Oral Hygiene*    
  Good  197 (32.6) 72 (49.3) 207 (45.0) 
  Moderate 108 (17.9) 22 (15.1) 84 (18.3) 
  Poor 190 (31.5) 46 (31.5) 140 (30.4) 
  Unknown 113 (18.0) 6 (4.1) 29 (6.3) 
Subset of patients with available data on HPV tumor markers*  
p16 expression (n=561)    
  Negative 237 (78.7) 56 (88.9) 169 (85.8) 
  Positive  64 (21.3) 7 (11.1) 28 (14.2) 
HPV16 DNA (n=715)    
  Negative 280 (72.7) 49 (64.5) 186 (73.2) 
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Description Larynx, N (%) Hypopharynx, N (%) Oral cavity N (%) 
  Positive 105 (27.3) 27 (35.5) 68 (26.8) 
p16/HPV16 DNA status (n=535)    
  p16 (–) DNA (–) 164 (56.8) 29 (50.0) 116 (61.7) 
  p16 (+) DNA (–) 35 (12.1) 4 (6.9) 18 (9.6) 
  p16 (+) DNA (+) 27 (9.3) 3 (5.2) 7 (3.7) 
  p16 (–) DNA (+) 63 (21.8) 22 (37.9) 47 (25.0) 
Abbreviations: HPV, Human Papillomavirus; p16, protein expression; BMI, body mass index. *Cases from Rome did 
not provide data on education, BMI, and oral health (dental care and oral hygiene). 
  605 
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 606 
Table 2A: Two-, 5- and 8-year overall survival after larynx and hypopharynx cancers in Europe  607 
 2-y survival (%) 
(95% CI) 
5-y survival (%) 
(95% CI) 
8-y survival (%) 
(95% CI) 
p-value‡ 
Overall 76.0 (72.7-79.0) 59.0 (55.2-62.7) 39.5 (33.7-45.3)  
Larynx 81.3 (77.8-84.3) 65.3 (61.1-69.2) 43.5 (36.4-50.4)  
Hypopharynx 55.3 (46.7-63.0) 34.6 (26.8-42.5) 23.8 (16.4-32.0) <0.0001 
Age at diagnosis, years     
  ≤50 75.9 (66.2-83.2) 55.0 (44.6-64.2) 44.1 (33.7-54.0)  
  51–60 76.4 (70.4-81.4) 63.0 (56.3-68.9) 41.9 (31.1-52.2)  
  61–70 76.6 (70.8-81.4) 61.0 (54.4-66.9) 40.9 (30.6-51.0)  
  ≥71 74.2 (65.4-81.1) 51.2 (41.5-60.0) 28.5 (16.7-41.4) 0.2071 
Sex     
  Male 75.5 (71.9-78.7) 59.4 (55.3-63.2) 40.0 (33.8-46.2)  
  Female 80.1 (69.6-87.4) 57.3 (45.2-67.7) 36.3 (21.0-51.8) 0.9185 
Smoking history     
  Never 85.6 (70.8-93.3) 77.7 (61.4-87.8) 72.1 (55.2-83.6)  
  Former 79.8 (74.2-84.2) 58.1 (51.4-64.3) 37.0 (25.9-48.0)  
  Current 72.7 (68.1-76.8) 57.5 (52.5-62.1) 37.4 (30.1-44.7) 0.0111 
Alcohol use history     
  Never 89.1 (73.3-95.8) 66.7 (47.7-80.1) .*  
  Former 73.0 (62.5-81.1) 57.2 (46.0-66.9) 46.8 (34.0-58.6)  
  Current 75.5 (71.8-78.9) 58.8 (54.6-62.8) 38.3 (31.7-44.7) 0.4631 
Stage at diagnosis     
  I  89.4 (82.7-93.6) 78.9 (70.7-85.0) 64.7 (50.2-75.9)  
  II 83.0 (74.0-89.1) 60.5 (50.0-70.0) 43.9 (31.6-55.5)  
  III 77.3 (68.8-83.8) 61.7 (52.2-69.9) 26.6 (9.50-47.5)  
  IV 63.5 (56.3-69.8) 43.7 (36.4-50.8) 22.9 (13.0-34.5) <0.0001 
Level of education      
  Finished primary school 74.5 (68.4-79.6) 58.1 (51.4-64.1) 34.7 (25.7-43.8)  
  Finished secondary school 76.7 (71.8-80.8) 61.5 (56.1-66.5) 45.6 (38.3-52.7)  
  University degree 74.2 (53.3-86.8) 58.1 (37.0-74.3) 29.0 (2.0-67.7) 0.2775 
BMI 2 years pre-diagnosis (kg/m2     
  Underweight (<18.5) 53.3 (17.7-79.6) 26.7 (4.1-57.9) .*  
  Normal  weight (18.524.9) 74.3 (68.7-79.0) 57.5 (51.4-63.1) 35.2 (27.1-43.4)  
  Overweight (2529.9) 80.5 (74.6-85.2) 64.2 (57.4-70.3) 52.9 (44.4-60.7)  
  Obesity (≥30) 72.4 (62.1-80.3) 61.1 (50.4-70.2) 29.3 (8.7-54.1) 0.0033 
Dental care     
  Good  82.6 (74.1-88.5) 65.0 (55.2-73.2) 53.8 (43.4-63.1)  
  Moderate 74.4 (70.2-78.1) 58.9 (54.2-63.2) 37.1 (29.5-44.7)  
  Poor 64.3 (34.3-83.3) 50.0 (22.9-72.2) .* 0.1878 
Oral Hygiene     
  Good  73.9 (68.1-78.9) 60.7 (54.4-66.4) 43.5 (34.4-52.1)  
  Moderate 77.3 (68.6-83.8) 65.2 (55.8-73.1) 36.7 (21.7-51.9)  
  Poor 76.9 (70.8-81.9) 56.4 (49.6-62.7) 40.5 (32.7-48.8) 0.3682 
p16 expression     
  Negative 78.2 (72.9-82.6) 58.7 (52.4-64.4) 36.9 (27.8-46.0)  
  Positive 80.8 (69.2-88.4) 59.3 (46.1-70.3) 37.1 (19.2-55.2) 0.7634 
p16/HPV16 DNA     
  p16 (–) DNA (–) 80.2 (73.6-85.3) 63.5 (55.6-70.3) 40.0 (27.1-52.5)  
  p16 (+) DNA (–) 78.1 (60.8-88.4) 51.8 (33.3-67.5) 36.1 (13.9-59.1)  
  p16 (+) DNA (+) 83.1 (64.0-92.6) 68.6 (48.3-82.3) 38.4 (12.8-64.0)  
  p16 (–) DNA (+) 71.0 (59.9-79.5) 49.6 (38.2-59.9) 27.6 (14.9-42.0) 0.1755 
Abbreviations: BMI, body mass index; HPV, Human Papillomavirus; p16, protein 16; CI, confidence interval;. ‡Log-rank test p-
value. *Could not be assessed. 
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Table 2B: Two-, 5- and 8-year overall survival after oral cavity cancer in Europe (table was not changed) 609 
 2-y survival (%) 
(95% CI) 
5-y survival (%) 
 (95% CI) 
8-y survival (%) 
(95% CI) 
p-value‡ 
Overall 72.7 (68.2-76.6) 55.0 (50.1-59.7) 30.3 (23.4-37.4)  
Age at diagnosis, years     
  ≤50 76.2 (66.2-83.7) 60.7 (49.9-69.9) 42.8 (28.4-56.4)  
  51–60 76.8 (69.3-82.7) 58.6 (50.3-66.0) 42.4 (32.0-52.5)  
  61–70 63.9 (54.2-72.1) 46.8 (37.2-55.9) 23.3 (12.2-36.3)  
  ≥71 72.6 (60.4-81.6) 52.1 (39.5-63.4) 11.5 (2.8-27.0) 0.0076 
Sex     
  Male 71.5 (66.0-76.2) 52.3 (46.4-57.8) 27.0 (19.9-34.6)  
  Female 75.7 (67.1-82.3) 61.6 (52.3-69.6) 35.8 (17.0-55.2) 0.0474 
Smoking history     
  Never 82.6 (70.7-89.9) 69.8 (56.8-79.6) .*  
  Former 75.1 (65.4-82.5) 58.1 (47.4-67.4) 29.5 (15.2-45.4)  
  Current 69.4 (63.5-74.6) 50.3 (44.0-56.2) 26.7 (19.3-34.6) 0.0211 
Alcohol use history     
  Never 72.1 (54.4-83.9) 57.6 (39.7-71.9) 43.5 (25.8-59.9)  
  Former 80.8 (68.0-88.9) 68.3 (54.4-78.7) 39.9 (23.3-56.1)  
  Current 71.3 (66.2-75.9) 52.5 (46.9-57.7) 29.3 (22.1-37.0) 0.4431   
Stage at diagnosis     
  I  89.3 (80.4-94.3) 78.4 (68.0-85.8) 57.6 (43.0-69.7)  
  II 79.7 (69.4-86.9) 63.9 (52.6-73.2) 33.3 (18.0-49.5)  
  III 72.5 (56.6-83.3) 54.5 (38.2-68.3) 19.5 (1.91-50.9)  
  IV 60.6 (51.2-68.8) 38.1 (29.2-46.9) 7.4 (0.8-24.7) <0.0001 
Level of education      
  Finished primary school 69.3 (60.3-76.6) 48.3 (39.1-56.8) 25.7 (15.2-37.5)  
  Finished secondary school 75.2 (69.5-80.0) 58.9 (52.6-64.6) 32.2 (23.5-41.3)  
  University degree 83.3 (56.8-94.3) 61.1 (35.3-79.2) 50.9 (23.6-73.0) 0.0175 
BMI 2 years pre-diagnosis (kg/m2)     
  Underweight (<18.5) 54.5 (25.4-76.5) 39.0 (14.3-63.3) .*  
  Normal  (18.5–24.9) 74.6 (67.7-80.3) 54.3 (46.8-61.2) 29.5 (19.4-40.3)  
  Overweight (2529.9) 77.9 (70.2-83.8) 63.1 (54.6-70.4) 34.8 (23.7-46.1)  
  Obese (≥30) 72.0 (57.4-82.4) 51.9 (37.3-64.6) 19.9 (2.0-51.5) 0.3210 
Dental care     
  Good  79.5 (68.7-86.9) 65.4 (53.7-74.8) 38.9 (20.7-56.8)  
  Moderate 72.8 (67.6-77.4) 54.1 (48.4-59.5) 29.0 (21.6-36.8)  
  Poor 74.1 (28.9-93.0) 44.4 (10.4-74.8) .* 0.0837 
Oral Hygiene     
  Good  74.5 (67.8-80.0) 59.7 (52.5-66.2) 36.8 (26.8-46.8)  
  Moderate 71.8 (60.4-80.5) 46.3 (34.8-57.0) 22.4 (9.9-37.9)  
  Poor 73.8 (65.2-80.6)  55.2(46.0-63.4) 26.2 (6.6-39.7) 0.1046 
p16 expression     
  Negative 68.8 (60.8-75.5) 49.4 (41.0-57.3) 27.7 (15.0-41.9)  
  Positive 70.1 (49.0-83.8) 66.2 (45.0-80.8) .* 0.7036 
p16/HPV16 DNA     
  p16 (–) DNA (–) 69.2 (59.3-77.2) 49.4 (39.1-59.0) 21.8 (6.6-42.7)  
  p16 (+) DNA (–) 66.7 (40.4-83.4) 61.1 (35.3-79.2) .*  
  p16 (+) DNA (+) 64.3 (15.2-90.2) 64.3 (15.2-90.2) .*  
  p16 (–) DNA (+) 72.8 (57.1-83.6) 51.6 (35.9-65.2)  51.6 (35.9-65.2)  0.7821 
Abbreviations: BMI, body mass index; HPV, Human Papilloma virus; p16, protein 16; CI, confidence interval. ‡Log-rank 
test p-value. *Could not be assessed.  
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Table 3: Hazard ratios of death after larynx and hypopharynx (combined) and oral cavity cancers in Europe 611 
 Larynx/hypopharynx Oral cavity 
 Multivariable HR (95% CI)* p-value‡ Multivariable HR (95%CI)* p-value‡ 
Age at diagnosis, years     
  ≤50 Reference  Reference  
  51–60 1.01 (0.72-1.43)  1.10 (0.75-1.60)  
  61–70 1.19 (0.84-1.67)  1.65 (1.12-2.44)  
  ≥71 1.61 (1.09-2.38) 0.0158 2.12 (1.35-3.33) 0.0012 
Sex     
  Male 0.96 (0.67-1.37)  1.42 (0.99-2.02)  
  Female Reference 0.8091 Reference 0.0474 
Smoking history     
  Never Reference  Reference  
  Former 1.87 (0.98-3.55)  1.15  (0.65-2.02)  
  Current 2.67 (1.40-5.08) 0.0010 2.16  (1.32-3.54) 0.0002 
Alcohol use history     
  Never Reference  Reference  
  Former 1.20 (0.62-2.30)  0.72 (0.37-1.37)  
 Current 1.22 (0.69-2.17) 0.9083 0.75 (0.43-1.31) 0.5753 
Stage at diagnosis     
  I  Reference  Reference  
  II 1.77 (1.15-2.72)  1.52 (0.94-2.47)  
  III 1.87 (1.23-2.86)  2.13 (1.24-3.67)  
  IV 2.60 (1.78-3.79) <0.0001 3.17 (2.05-4.89) <0.0001 
Education     
  Primary school 0.93 (0.51-1.72)  1.10 (0.52-2.35)  
  Secondary school 0.73 (0.40-1.34)  0.85 (0.41-1.78)  
  University degree Reference 0.2069 Reference 0.2208 
BMI 2 years pre-diagnosis (kg/m2)     
  Underweight ( <18.5) 1.64 (0.75-3.60)  1.83 (0.84-4.00)  
  Normal (18.5–24.9) Reference  Reference  
  Overweight (25.0–29.9) 0.75 (0.58-0.98)  0.98 (0.72-1.34)  
  Obese (≥30) 1.09 (0.78-1.52)  0.0970 1.41 (0.92-2.18) 0.0592 
Tumor site     
  Larynx Reference  N/A  
  Hypopharynx 2.29 (1.79-2.94) <0.0001   
Abbreviation: BMI, body mass index; HR=hazard ratio of death; CI=confidence interval. *Additionally adjusted for year of 
diagnosis. ‡Likelihood ratio test. 
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Modified supplementary Tables S1 and S2 613 
Table S1: Hazard ratios of death after larynx, hypopharynx, and oral cavity cancers using smoking and drinking 614 
duration or intensity.& 615 
 Larynx/hypopharynx Oral cavity 
Multivariable HR£ 
(95% CI) 
p-value† Multivariable HR£ 
(95% CI) 
p-value† 
Smoking duration, years     
Never smokers Reference  Reference  
  1–9  4.14 (1.13-15.3)  0.55 (0.16-1.89)  
  10–19 3.53 (1.28-9.74)  1.35 (0.60-3.05)  
  20–29 1.93 (0.78-4.81)  1.45 (0.78-2.72)  
  30–39 2.88 (1.22-6.78)  2.09 (1.21-3.63)  
  ≥40 3.98 (1.70-9.34) 0.0006 2.92 (1.70-5.02) <0.0001 
Smoking intensity, pack/years     
Never smokers Reference  Reference  
  <20  2.67 (1.10-6.48)  1.61 (0.93 -2.82)  
  20–39 3.12 (1.33-7.32)  2.53 (1.47-4.34)  
  40–59 3.69 (1.56-8.72)  2.28 (1.28-4.07)  
  ≥60 3.37 (1.41-8.09) 0.0082 2.47 (1.34-4.59) 0.0156 
Drinking duration, years     
Never drinkers Reference  Reference  
  1–9  1.15 (0.30-4.36)  .*  
  10–19 1.44 (0.54-3.82)  0.57 (0.26-1.27)  
  20–29 1.31 (0.60-2.84)  0.62 (0.32-1.21)  
  30–39 1.32 (0.63-2.74)  0.71 (0.39-1.33)  
  ≥40 1.43 (0.70-2.94) 0.5036 0.80 (0.44-1.47) 0.0167 
Drinking intensity, drinks/day     
  <5 drinks per day Reference  Reference  
  ≥ 5 drinks per day 0.97 (0.74-1.27)    0.0655 1.02 (0.74-1.42) 0.8886 
&Cases from Rome were excluded due to lack of data. Missing information from other centers: smoking 
duration: larynx/hypopharynx (LH)=4, oral cancer (OC)=3; smoking intensity: LH=6, OC=4. ; drinking duration: 
LH =4, OC=2; drinking intensity, LH=8, OC=5. £Adjusted for sex, age and stage at diagnosis, education, year of 
diagnosis, and tumor site. †Likelihood ratio test. *Could not be assessed. 
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Table S2: Hazard ratios of death by p16 expression and HVP16 DNA status after larynx, hypopharynx, and 617 
 oral cancers in Europe 618 
 619 
 Number Univariable HR* 
(95% CI) 
p-value† Multivariable HR* 
(95% CI) 
p-value† 
p16 expression      
  Negative 462 Reference  Reference  
  Positive 99 0.91 (0.66-1.25) 0.5699 0.99 (0.72-1.37) 0.9451 
p16/HPV16 DNA      
  p16 (–) DNA (–) 309 Reference  Reference  
  P16 (+) DNA (–) 57 1.13 (0.76-1.68)  1.09 (0.73-1.64)  
  P16 (+) DNA (+) 37 0.86 (0.51-1.44)  1.11 (0.65-1.89)  
  p16 (–) DNA (+) 132 1.17 (0.88-1.56) 0.5795 1.21 (0.90-1.62)  0.6554 
Abbreviations: HPV, Human Papilloma virus; p16, protein expression. *Adjusted by age and stage at 
diagnosis, sex, smoking history, year of diagnosis, and tumor site. †Likelihood ratio test. 
 620 
 621 
Figure legends 622 
 623 
1- Overall survival from head and neck cancers by: A, anatomic site; B, larynx subsite; C, 624 
hypopharynx subsite; and D, oral cavity subsite. 625 
 626 
2- The hazard ratios of death by HPV tumor markers among patients with larynx, hypopharynx, 627 
and oral cavity cancers, 2002–2011, the ARCAGE study 628 
